{"schema_version":"secwatch.filing_event.v1","accession":"0000049071-24-000021","form_type":"8-K","ticker":"HUM","cik":"0000049071","company_name":"HUMANA INC","filed_at":"2024-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.636783+00:00","generated_at":"2026-06-03T10:03:51.467550+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Humana Q1 GAAP EPS $6.11 vs $9.87 YoY; guidance revised down on GAAP but adjusted affirmed","bullets":["GAAP EPS $6.11, down from $9.87 YoY; adjusted EPS $7.23 vs $9.38 YoY.","Revenue $29.6B, up from $26.7B YoY; benefit ratio rose to 88.9% from 85.5%.","FY 2024 GAAP EPS guidance lowered to ~$13.93 from ~$14.87; adjusted EPS affirmed at ~$16.00.","Individual Medicare Advantage membership growth raised by 50k to ~150k (2.8% annual).","Medicaid expansion with contract wins in Florida, Texas, and Virginia."],"urls":{"canonical":"https://secwatch.observer/filing/0000049071-24-000021","json":"https://secwatch.observer/filing/0000049071-24-000021.json","markdown":"https://secwatch.observer/filing/0000049071-24-000021.md","text":"https://secwatch.observer/filing/0000049071-24-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/49071/000004907124000021/0000049071-24-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/49071/000004907124000021/hum-20240424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T10:03:51.467550+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7b21f4e6956678ed3a62788c0b7fc902ff9c80d9","claim":"HUMANA INC reported year ending December 31, 2024 results: EPS $16.00. Guidance reaffirmed.","evidence_excerpt":"Humana revised its GAAP EPS guidance for the year ending December 31, 2024 (FY 2024) to approximately $13.93 from approximately $14.87, while affirming its Adjusted EPS guidance of approximately $16.00.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/49071/000004907124000021/0000049071-24-000021-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ending December 31, 2024"},{"label":"EPS","value":"$16.00"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"7c0b653de5782197a261c9403ff76dfa5de13e6e","claim":"HUMANA INC reported quarter ended March 31, 2024 results: revenue $29,611, EPS $6.11.","evidence_excerpt":"and segment statistics comparing 1Q24 to 1Q23 follows. 2 Humana Inc. Summary of Results ($ in millions, except per share amounts) 1Q24 (a) 1Q23 (a) CONSOLIDATED Revenues $29,611 $26,742 Revenues - Adjusted (non-GAAP) $29,332 $25,652 Pretax results $1,014 $1,614 Pretax results - Adjusted (non-GAAP) $1,191 $1,552 EPS $6.11 $9.87 EPS - Adjusted (non-GAAP)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/49071/000004907124000021/0000049071-24-000021-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Revenue","value":"$29,611"},{"label":"EPS","value":"$6.11"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}